Reverse Genetic Approaches for the Development of Zika Vaccines and Therapeutics

Overview

Journal Curr Opin Virol

Publisher Elsevier

Specialty Microbiology

Date 2020 Jun 22

PMID 32563700

Citations 1

Authors

Camila R Fontes-Garfias

Coleman K Baker

Pei-Yong Shi

Affiliations

Soon will be listed here.

Abstract

In 2015-2016, the little known Zika virus (ZIKV) caused an epidemic, in which it became recognized as a unique human pathogen associated with a range of devastating congenital abnormalities collectively categorized as congenital Zika syndrome (CZS). In adults, the virus can trigger the autoimmune disorder Guillain-Barré syndrome (GBS), characterized by ascending paralysis. In February 2016, the World Health Organization (WHO) declared ZIKV to be a Public Health Emergency of International Concern. The global public health problem prompted academia, industry, and governments worldwide to initiate development of an effective vaccine to prevent another ZIKV epidemic that would put millions at risk. The development of reverse genetic systems for the study and manipulation of RNA viral genomes has revolutionized the field of virology, providing platforms for vaccine and antiviral development. In this review, we discuss the impact of reverse genetic systems on the rapid progress of ZIKV vaccines and antiviral therapeutics.

Citing Articles

Construction of Stable Reporter Flaviviruses and Their Applications.

Baker C, Shi P Viruses. 2020; 12(10).

PMID: 32992987 PMC: 7599567. DOI: 10.3390/v12101082.

References

Zou J, Shi P . Strategies for Zika drug discovery. Curr Opin Virol. 2019; 35:19-26. DOI: 10.1016/j.coviro.2019.01.005. View

Shan C, Xie X, Ren P, Loeffelholz M, Yang Y, Furuya A . A Rapid Zika Diagnostic Assay to Measure Neutralizing Antibodies in Patients. EBioMedicine. 2017; 17:157-162. PMC: 5360589. DOI: 10.1016/j.ebiom.2017.03.006. View

Zhang X, Xie X, Xia H, Zou J, Huang L, Popov V . Zika Virus NS2A-Mediated Virion Assembly. mBio. 2019; 10(5). PMC: 6819661. DOI: 10.1128/mBio.02375-19. View

Atieh T, Baronti C, de Lamballerie X, Nougairede A . Simple reverse genetics systems for Asian and African Zika viruses. Sci Rep. 2016; 6:39384. PMC: 5171905. DOI: 10.1038/srep39384. View

Weaver S, Costa F, Garcia-Blanco M, Ko A, Ribeiro G, Saade G . Zika virus: History, emergence, biology, and prospects for control. Antiviral Res. 2016; 130:69-80. PMC: 4851879. DOI: 10.1016/j.antiviral.2016.03.010. View

Barrett A . Current status of Zika vaccine development: Zika vaccines advance into clinical evaluation. NPJ Vaccines. 2018; 3:24. PMC: 5995964. DOI: 10.1038/s41541-018-0061-9. View

Li X, Dong H, Wang H, Huang X, Qiu Y, Ji X . Development of a chimeric Zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone. Nat Commun. 2018; 9(1):673. PMC: 5813210. DOI: 10.1038/s41467-018-02975-w. View

Xie X, Yang Y, Muruato A, Zou J, Shan C, Nunes B . Understanding Zika Virus Stability and Developing a Chimeric Vaccine through Functional Analysis. mBio. 2017; 8(1). PMC: 5296601. DOI: 10.1128/mBio.02134-16. View

Maeda A, Maeda J . Review of diagnostic plaque reduction neutralization tests for flavivirus infection. Vet J. 2012; 195(1):33-40. DOI: 10.1016/j.tvjl.2012.08.019. View

10.

Thisyakorn U, Thisyakorn C . Latest developments and future directions in dengue vaccines. Ther Adv Vaccines. 2014; 2(1):3-9. PMC: 3991153. DOI: 10.1177/2051013613507862. View

11.

Chiocca E, Rabkin S . Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res. 2014; 2(4):295-300. PMC: 4303349. DOI: 10.1158/2326-6066.CIR-14-0015. View

12.

Pierson T, Sanchez M, Puffer B, Ahmed A, Geiss B, Valentine L . A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology. 2005; 346(1):53-65. DOI: 10.1016/j.virol.2005.10.030. View

13.

Shan C, Muruato A, Nunes B, Luo H, Xie X, Medeiros D . A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models. Nat Med. 2017; 23(6):763-767. PMC: 6276361. DOI: 10.1038/nm.4322. View

14.

Xia H, Luo H, Shan C, Muruato A, Nunes B, Medeiros D . An evolutionary NS1 mutation enhances Zika virus evasion of host interferon induction. Nat Commun. 2018; 9(1):414. PMC: 5788864. DOI: 10.1038/s41467-017-02816-2. View

15.

Aliota M, Bassit L, Bradrick S, Cox B, Garcia-Blanco M, Gavegnano C . Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus Network. Antiviral Res. 2017; 144:223-246. PMC: 5920658. DOI: 10.1016/j.antiviral.2017.06.001. View

16.

Garg H, Sedano M, Plata G, Punke E, Joshi A . Development of Virus-Like-Particle Vaccine and Reporter Assay for Zika Virus. J Virol. 2017; 91(20). PMC: 5625514. DOI: 10.1128/JVI.00834-17. View

17.

Xie X, Shi P . Repurposing an HIV Drug for Zika Virus Therapy. Mol Ther. 2019; 27(12):2064-2066. PMC: 6904818. DOI: 10.1016/j.ymthe.2019.10.004. View

18.

Li J, Deng C, Gu D, Li X, Shi L, He J . Development of a replicon cell line-based high throughput antiviral assay for screening inhibitors of Zika virus. Antiviral Res. 2017; 150:148-154. DOI: 10.1016/j.antiviral.2017.12.017. View

19.

Tebas P, Roberts C, Muthumani K, Reuschel E, Kudchodkar S, Zaidi F . Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine. N Engl J Med. 2021; 385(12):e35. PMC: 6824915. DOI: 10.1056/NEJMoa1708120. View

20.

Petersen L, Jamieson D, Powers A, Honein M . Zika Virus. N Engl J Med. 2016; 374(16):1552-63. DOI: 10.1056/NEJMra1602113. View